In Segment A, individuals will get various doses and schedules of oral ABBV-744 tablet to detect Protected dosing routine. Additional individuals will likely be enrolled within the identified monotherapy dosign regimen. In Section B, members will get oral ruxolitinib and ABBV-744 will be provided as "insert-on" therapy. In Phase C, https://judyk665whr8.bloggadores.com/profile